ARTICLE | Clinical News
Subcutaneous elamipretide: Ph I started
November 15, 2016 9:24 PM UTC
Stealth began the open-label, U.S. Phase I ReCLAIM trial to evaluate 40 mg subcutaneous elamipretide once daily for 12 weeks in about 40 patients ages ≥55....
BCIQ Company Profiles
BCIQ Target Profiles